Scarica l'app Stockscreener
1.14
1.72%
-0.02
Dopo l'orario di chiusura:
1.14
Lava Therapeutics Nv Borsa (LVTX) Ultime notizie
Investors Aren't Buying LAVA Therapeutics N.V.'s (NASDAQ:LVTX) Revenues - simplywall.st
Lava Therapeutics’ SWOT analysis: biotech stock faces crossroads after asset cut - Investing.com India
LAVA Therapeutics (NASDAQ:LVTX) Receives Neutral Rating from HC Wainwright - Defense World
Leerink cuts Lava Therapeutics stock target to $1 By Investing.com - Investing.com Canada
Lava Therapeutics’ SWOT analysis: biotech stock faces crossroads after asset cut By Investing.com - Investing.com South Africa
Leerink cuts Lava Therapeutics stock target to $1 - Investing.com
JMP maintains LAVA Therapeutics stock Market Perform rating By Investing.com - Investing.com Australia
JMP maintains LAVA Therapeutics stock Market Perform rating - Investing.com
Lava Therapeutics Reports 2024 Financial Results - TipRanks
LAVA Therapeutics NV earnings beat by $0.16, revenue topped estimates - Investing.com Australia
LAVA Therapeutics N.V. (LVTX) reports earnings - Quartz
LAVA Therapeutics NV SEC 10-K Report - TradingView
LAVA Therapeutics NV reports results for the quarter ended December 31Earnings Summary - TradingView
LAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update - GlobeNewswire
LAVA Therapeutics Q4 Basic EPS USD -0.14 - MarketScreener
Lava Therapeutics’ SWOT analysis: biotech stock faces crossroads amid pipeline shifts By Investing.com - Investing.com South Africa
Lava Therapeutics’ SWOT analysis: biotech stock faces crossroads amid pipeline shifts - Investing.com
Analyst Downgrades LAVA Therapeutics, Sees Pipeline Overhang - Benzinga
This Constellation Brands Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday - Benzinga
LAVA Therapeutics Reviews Strategic Alternatives, Announces 30% Staff Cut - Nasdaq
LAVA Therapeutics Announces Restructuring Plan for 2025 - TipRanks
LAVA Announces Evaluation of Strategic Options - GlobeNewswire
Can LAVA Therapeutics Find a Buyer? Company Cuts 30% of Staff While Exploring Strategic Options - StockTitan
LVTX stock touches 52-week low at $0.88 amid market challenges - Investing.com Australia
LVTX stock touches 52-week low at $0.88 amid market challenges By Investing.com - Investing.com South Africa
LAVA Therapeutics (NASDAQ:LVTX) Stock Price Down 4.6% – Here’s What Happened - Defense World
RNA Editing Market Top Companies StudyQIAGEN N.V., UniquQuire - openPR
LAVA Therapeutics begins trial for cancer treatment - Investing.com India
LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers - GlobeNewswire
LAVA Therapeutics Initiates Phase 1 Trial for Novel Leukemia Treatment LAVA-1266 - StockTitan
LAVA Therapeutics NV (LVTX)’S -5.56% Retreat Makes It Worth Considering Again - Stocks Register
LAVA Therapeutics NV Files 8-K with SEC, Transitioning to U.S. Domestic Issuer Status - Defense World
LVTX stock touches 52-week low at $0.95 amid market challenges - Investing.com
H.C. Wainwright maintains Buy on Lava Therapeutics shares despite pipeline reprioritization By Investing.com - Investing.com South Africa
H.C. Wainwright maintains Buy on Lava Therapeutics shares despite pipeline reprioritization - Investing.com
LAVA Therapeutics stock hits 52-week low at $0.98 - Investing.com
Lava Therapeutics' SWOT analysis: stock faces challenges after key asset discontinuation - Investing.com
Research Analysts Issue Forecasts for LVTX Q1 Earnings - Defense World
LAVA Therapeutics (NASDAQ:LVTX) Rating Lowered to “Hold” at Leerink Partnrs - Defense World
Leerink Partners Downgrades LAVA Therapeutics N.V. (LVTX) - MSN
Leerink cuts Lava Therapeutics stcok to Market Perform By Investing.com - Investing.com Nigeria
Leerink cuts Lava Therapeutics stcok to Market Perform - Investing.com India
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):